Nebenwirkungen · Yescarta
Yescarta 0.4 – 2 × 108 cells dispersion for infusion · Abschnitt 4.8 · PDF-Seite 12–13
HOS-139699 · Präparat HOS-098384
12 System Organ Class (SOC) Frequency Adverse reactions Common Infusion related reaction Pain Uncommon Multiple organ dysfunction syndrome * Haemophagocytic lymphohistiocytosis has been reported in the setting of CRS ** Hyperuricemia was identified from a pooled analysis of 227 adult patients treated with Yescarta in ZUMA-1 and ZUMA- 5 *** Dysphagia has been reported in the setting of neurologic toxicity and encephalopathy # Frequency based on Grade 3 or higher laboratory parameter ## Most cases of cerebral oedema occurred in patients with ICANS
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-08T14:29:00Z · SHA-256 7364b8713752a41eb6e8333150b68c1c6ab4a679e9b42caeedeacec6f055396e · Passage 520a56b5e8013e7602d727080f2fe321cf0bae7aba672a5406505698499a1e04 · Zeichen 11872–12697 im Abschnitt